A cannabinoid composition for enabling nearly simultaneous sublingual delivery of at least one cannabinoid, and an anti-fungal agent to the digestive tract of a subject. The composition includes cannabidiol, caprylic acid, lecithin, and at least one terpene. The ratio of cannabidiol to caprylic acid is between 10:1 and 25:1 on a weight to weight (w:w) basis. Preferably, the lecithin is liquid soy lecithin, the cannabidiol is an isolate having at least 95% purity, and the at least one terpene is engineered to have a therapeutic entourage effect in combination with the at least one cannabinoid in vivo.
